AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05401812
Drug: Intravenous glucocorticoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone, dexamethasone, or methylprednisolone
Trial: NCT04523142
Drug: CyclASol Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A solution in vehicle
Trial: NCT05501912
Drug: ABM-1310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level.
Trial: NCT06049667
Drug: NTQ2494 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
Trial: NCT05773703
Drug: PSMA-Targeted [In-111]-Labeled Trillium Compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotracer
Trial: NCT06378983
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin
Trial: NCT05298306
Drug: LAT8881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A
Trial: NCT05298306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo'given as a single intravenous infusion at all dose levels
Trial: NCT05331300
Drug: LASN01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating single and multiple doses of LASN01
Trial: NCT05331300
Drug: LASN01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LASN01 will be administered intravenously
Trial: NCT05331300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of matching placebo
Trial: NCT05331300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously
Trial: NCT06427343
Drug: High-dose ferric derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.~In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up.
Trial: NCT06427343
Drug: Low-dose ferric derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the low-dose group, participants will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \>20% during follow-up.
Trial: NCT04755322
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg
Trial: NCT06342778
Drug: Doxylamine + Pyridoxine
RxNorm normalized name: doxylamine / pyridoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of R or T drug in each of 2 periods of the study under fed conditions
Trial: NCT05314569
Drug: Fentanyl- midazolam
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery
Trial: NCT06528249
Drug: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
RxNorm normalized name: ACELLULAR TISSUE ENGINEERED VESSEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Trial: NCT06172127
Drug: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
RxNorm normalized name: Phesgo 1,200 MG / 600 MG / 30,000 UNT per 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
Trial: NCT06172127
Drug: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
RxNorm normalized name: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
Trial: NCT05222529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Trial: NCT04964843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04752722
Drug: EG-70 (phase 1)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
Trial: NCT05215990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
Trial: NCT04752722
Drug: EG-70 (phase 2)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
Trial: NCT04996017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
Trial: NCT06447987
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05270213
Drug: RBS2418
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
Trial: NCT04886284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo
Trial: NCT04932512
Drug: ION224
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION224 will be administered by SC injection.
Trial: NCT05281562
Drug: L-Arginine Powder
RxNorm normalized name: L-Arginine powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 4.5 grams L-Arginine, powder form.
Trial: NCT06589830
Drug: TL938 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05165225
Drug: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
Trial: NCT06337422
Drug: Celecoxib 200 mg capsule
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg capsule
Trial: NCT04732169
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
Trial: NCT04705909
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
Trial: NCT06556641
Drug: GZR33 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as once daily subcutaneous dose
Trial: NCT06556641
Drug: GZR101 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as once daily subcutaneous dose
Trial: NCT06556641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as once daily subcutaneous dose
Trial: NCT05892653
Drug: ABM-1310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed.
Trial: NCT05030857
Drug: GLPG4716
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
Trial: NCT06010732
Drug: 0 ppm F (placebo, negative control)
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Trial: NCT05129423
Drug: MTPS9579A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTPS9579A will be administered.
Trial: NCT05129423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched with MTPS9579A will be administered.
Trial: NCT04662580
Drug: ARX517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
Trial: NCT03720483
Drug: N-acetyl cysteine then Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive N-acetyl cysteine first followed by Placebo
Trial: NCT03720483
Drug: Placebo then N-acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive Placebo first followed by N-acetyl cysteine
Trial: NCT05239728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06307600
Drug: RD06-03 cell injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this intervention will use RD06-03 cell injection with 3 dose dose 1: 1×10\^5 CAR+ T Cells/kg dose 2: 3×10\^5 CAR+ T Cells/kg dose 3: 5×10\^5 CAR+ T Cells/kg Dosage form: IV injection Frequency of administration：1 time
Trial: NCT06008028
Drug: BR1015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06008028
Drug: BR1015-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06008028
Drug: BR1015-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06252194
Drug: Metformin and doxycycline
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg tablet twice daily
Trial: NCT05035810
Drug: Corticosteroid Injection given in A-B order
RxNorm normalized name: Orderable Drug Form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
Trial: NCT05511519
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet manufactured to match ATI-450 in appearance
Trial: NCT05035810
Drug: Procedure: Corticosteroid Injection given in B-A order
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
Trial: NCT04216290
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06319118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.
Trial: NCT06066528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly subcutaneous injection
Trial: NCT05260021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06201247
Drug: JD123 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
Trial: NCT05523297
Drug: Frozen Plasma Product, Human
RxNorm normalized name: Frozen plasma product, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
Trial: NCT06528431
Drug: Clinical tapering strategy
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
Trial: NCT04718961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules matched to study drug minus active substance.
Trial: NCT06557174
Drug: mycophenolate mofetil， MMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral 0.2g
Trial: NCT05556291
Drug: Combinations of Oral Blood Glucose Lowering Drugs
RxNorm normalized name: Combinations of oral blood glucose lowering drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ertugliflozin and Sitagliptin
Trial: NCT06151431
Drug: Alpha-Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Trial: NCT06151431
Drug: α-adrenergic receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Trial: NCT05936268
Drug: Genakumab for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/1ml/bottle
Trial: NCT05293964
Drug: SIM0270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIM0270 is an oral, selective estrogen receptor degrader (SERD)
Trial: NCT06242795
Drug: 7% Hypertonic Saline via nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
Trial: NCT05838573
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
Trial: NCT05660681
Drug: polyethylene glycol 400 0.4%/propylene glycol 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop with active agents from the OTC Monograph.
Trial: NCT05437263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT05670847
Drug: Exogenous ketone ester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
Trial: NCT06517823
Drug: Etoricoxib fixed dose
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill of 90 mg a day
Trial: NCT02675842
Drug: Smoked Cannabis High CBD/low THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
Trial: NCT05136690
Drug: MK-4334
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4334 250 mg capsule taken by mouth.
Trial: NCT05136690
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch.
Trial: NCT05136690
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken by mouth.
Trial: NCT06299124
Drug: RGT-419B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RGT-419B will be administered orally
Trial: NCT06680947
Drug: 610
RxNorm normalized name: AY-6108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injection.
Trial: NCT06680947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injection.
Trial: NCT02675842
Drug: Smoked Placebo Cannabis Low CBD/low THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
Trial: NCT05171946
Drug: S.opt.FL COVID-19 pDNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dose: (1mg) level
Trial: NCT05171946
Drug: S.opt.FL COVID-19 pDNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-Dose: (2mg) level
Trial: NCT05171946
Drug: S.opt.FL COVID-19 pDNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose: (4mg) level
Trial: NCT06709417
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )
Trial: NCT06708845
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting chemotherapy
Trial: NCT06383572
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT05578872
Drug: ANV419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANV419 administered by intravenous (IV) infusion
Trial: NCT05742698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
Trial: NCT04855929
Drug: ANV419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANV419 administered by intravenous (IV) infusion
Trial: NCT05086250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
Trial: NCT05086250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
Trial: NCT06497127
Drug: BW-00112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW-00112 or volume-matched placebo on Day 1 and Day 90
Trial: NCT05356078
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class
Trial: NCT06402630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Trial: NCT05971862
Drug: SKI-G-801
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
Trial: NCT06111521
Drug: LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06111521
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally